Dysfunctional microglia and tau pathology in Alzheimer's disease
- PMID: 36302379
- DOI: 10.1515/revneuro-2022-0087
Dysfunctional microglia and tau pathology in Alzheimer's disease
Abstract
Extensive human studies and animal models show that chronic immune system stimulation involving microglia, inflammasome, complement activation, synthesis of cytokines, and reactive oxygen species exacerbates neurodegeneration in Alzheimer's disease (AD) and other tauopathies. Abnormalities in tau, Aβ, and microglial activation are frequently observed in dementia patients and indicate that these elements may work in concert to cause cognitive impairment. Contradicting reports from postmortem studies demonstrating the presence of Aβ aggregates in the brains of cognitively healthy individuals, as well as other investigations, show that tau aggregation is more strongly associated with synapse loss, neurodegeneration, and cognitive decline than amyloid pathology. Tau association with microtubules' surface promotes their growth and maintains their assembly, dynamicity, and stability. In contrast, the reduced affinity of hyperphosphorylated and mislocalized tau to microtubules leads to axonal deficits and neurofibrillary tangles (NFTs). Loss of microglial neuroprotective and phagocytic functions, as indicated by the faulty clearance of amyloid plaques, as well as correlations between microglial activation and tau tangle spread, all demonstrate the critical involvement of malfunctioning microglia in driving tau propagation. This review discusses the recent reports on the contribution of microglial cells to the development and progression of tau pathology. The detailed study of pathogenic mechanisms involved in interactions between neuroinflammation and tau spread is critical in identifying the targets for efficacious treatment strategies in AD.
Keywords: Alzheimer’s disease; endolysosomal degradation; microglia; neurofibrillary tangles; tau protein.
© 2022 Walter de Gruyter GmbH, Berlin/Boston.
References
-
- Alzheimer’s disease facts and figures (2020). Alzheimer’s Dementia 16: 391–460.
-
- Ahmed, T., Van der Jeugd, A., Blum, D., Galas, M.-C., D’Hooge, R., Buee, L., and Balschun, D. (2014). Cognition and hippocampal synaptic plasticity in mice with a homozygous tau deletion. Neurobiol. Aging 35: 2474–2478, https://doi.org/10.1016/j.neurobiolaging.2014.05.005 . - DOI
-
- Annadurai, N., De Sanctis, J.B., Hajdúch, M., and Das, V. (2021). Tau secretion and propagation: perspectives for potential preventive interventions in Alzheimer’s disease and other tauopathies. Exp. Neurol. 343: 113756, https://doi.org/10.1016/j.expneurol.2021.113756 . - DOI
-
- Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S., and Ikezu, T. (2015). Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat. Neurosci. 18: 1584–1593, https://doi.org/10.1038/nn.4132 . - DOI
-
- Barthélemy, N.R., Bateman, R.J., Hirtz, C., Marin, P., Becher, F., Sato, C., Gabelle, A., and Lehmann, S. (2020). Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification. Alzheimer’s Res. Ther. 12: 1–11, https://doi.org/10.1186/s13195-020-00596-4 . - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical